Companies Dominating the Erythropoietin Stimulating Agents Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson Services, Inc.
- Thermo Fisher Scientific
- Fuji Pharma
- Cigna
- Sandoz International GmbH
- Biocon
- 3SBio Group
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of erythropoietin stimulating agents is estimated at USD 19.65 billion.
Erythropoietin Stimulating Agents Market size was valued at USD 18.08 billion in 2024 and is likely to cross USD 63.91 billion by 2037, registering more than 10.2% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is poised to hold largest revenue share by 2037, driven by growing developments and innovations in the field of medicine in the region.
The major players in the market are Amgen Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Thermo Fisher Scientific, Fuji Pharma, Cigna, Sandoz International GmbH, Biocon, 3SBio Group, and others.
